[Research ethics and developing countries].
Developing countries are a breeding ground for research, especially for infectious diseases and HIV. On one hand, due to the prevalence of these diseases in this part of the world, and on the other, due to its needs in terms of research, disease prevention and heath care. The actions taken in the fight against HIV infection over the past years, considering that the urgent state of the health care situation has been a sensitive issue for ethical deviation evident in the following examples: Nonoxynol 9 trial (1996-1999) in Cameroon; Tenofovir trial (2003-2005) in Cameroon; Trials of fusion inhibitors in Latin America. No sanctions were imposed due to these deviations, and there was no possibility of recourse. What can these poor states do faced with health care emergencies, the extreme vulnerability of these populations and the big powerful pharmaceutical companies whose turnover or even profits are higher than the GDP of these countries? It is of the utmost importance that an international court of appeal be established to handle litigation regarding research related issues and the fair sharing of the profits resulting from research. The protection of vulnerable populations and the strict respect of ethical rules can only be implemented to the fullest if sanctions are applied to abusers.
Dieudonné
Désiré Adiogo
DA
Université de Yaounde I, Faculté de Médecine et des Sciences biomédicales, Cameroun.
D001675:Bioethics; D003906:Developing Countries; D003967:Diarrhea / Q000517:prevention & control; D005260:Female; D015658:HIV Infections / Q000517:prevention & control; D006801:Humans; D007223:Infant; D007226:Infant Mortality; D008288:Malaria / Q000517:prevention & control; D044342:Malnutrition / Q000517:prevention & control; D008428:Maternal Mortality; D011247:Pregnancy; D012106:Research / Q000592:standards*